Kyle Leeman

Kyle Leeman is an experienced professional in the field of analytical development and quality control, currently serving as the Vice President of Analytical R&D and QC at Bristol Myers Squibb since January 2024. Previously, Kyle held the position of Vice President of Analytical Development and QC at Mirati Therapeutics from October 2021, and served as Executive Director of Analytical Development at Neurocrine Biosciences from October 2017 to October 2021, overseeing the analytical development supporting drug substance and product development. Prior to that role, Kyle worked at Pfizer as an Associate Research Fellow for 27 years, specializing in analytical chemistry for late-stage drug substance development. Kyle earned a Bachelor of Science degree in Chemistry from Quinnipiac University between 1986 and 1990.